Select a State

Global health R&D delivers for Georgia

US government investment in global health R&D has delivered

$349.1 million
to Georgia research institutions
5,800+ new jobs
for Georgia

Neglected diseases in Georgia

Chikungunya cases
48
Dengue cases
70
HIV diagnoses
24,140
Malaria cases
534
Tuberculosis cases
3,299
West Nile cases
190
Zika cases
110

Georgia's top USG-funded global health R&D institutions

Centers for Disease Control and Prevention (self-funding & other agency transfers)
$129.8 million
Emory University
$147.8 million
University of Georgia
$61.0 million
Morehouse School of Medicine
$4.7 million
Georgia State University
$4.1 million
Augusta University College of Education (formally Georgia Regents University)
$745 thousand
Kennesaw State University
$481 thousand
Mercer University
$252 thousand
Medical College of Georgia
$204 thousand
Atlanta Research and Education Foundation
$55 thousand

Georgia industry in global health R&D

Arthify
Location(s):
Duluth
Geovax
Location(s):
Atlanta
Novartis
Location(s):
Duluth
Pathens
Location(s):
Athens
Sanofi
Location(s):
Forest Park
Westat
Location(s):
Atlanta

Georgia's top areas of global health R&D by USG funding

29.9%
HIV/AIDS
13.9%
Malaria
25.3%
Tuberculosis
4.2%
Ebola/viral hemorrhagic fevers
3.2%
Bacteria pneumonia & meningitis
16.2%
Neglected tropical diseases
Buruli ulcer
Dengue
Helminths
Kinetoplastids
Trachoma
7.3%
Other
Diarrheal diseases
Non-allocable
Salmonella infections

Global health R&D at work in Georgia

Emory University School of Medicine is supporting early stage clinical trials of a vaccine to prevent infection with chikungunya virus. Chikungunya is transmitted by mosquitoes and can cause persistent, debilitating joint pain. The virus, originating in Africa, arrived in the Caribbean several years ago and has since infected more than 2 million people in the Americas, including in the Florida Keys. If approved, the vaccine could be a powerful tool for protection.

Footnotes